Literature DB >> 24002389

How to manage infected aortic endografts.

B J Herdrich1, R M Fairman.   

Abstract

Aortic endografts have become the preferred treatment for aneurysms of the descending thoracic aorta and the infrarenal aorta. The prevalence of endograft infections is about 0.6%, and with the growing number of patients with aortic endografts, the number of patients with endograft infections has also increased. It is important for physicians who treat aneurysmal disease with endografting to understand the pathophysiology, work-up, and treatment options available. Currently, the mainstay of treatment is prolonged antibiotic therapy, explant of all prosthetic material, and reconstruction of the vasculature with either an in situ or extra-anatomic bypass. However, there is a growing experience of less invasive treatment strategies that can be used in patients who cannot withstand an operation of this magnitude.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002389

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  4 in total

Review 1.  How To Diagnose and Manage Infected Endografts after Endovascular Aneurysm Repair.

Authors:  Carlo Setacci; Emiliano Chisci; Francesco Setacci; Leonardo Ercolini; Gianmarco de Donato; Nicola Troisi; Giuseppe Galzerano; Stefano Michelagnoli
Journal:  Aorta (Stamford)       Date:  2014-12-01

2.  Secondary aortoduodenal fistula and the unrecognised herald bleed.

Authors:  Francesc Simó Alari; Esther Molina González; Israel Gutierrez; Aïcha Ahamdanech-Idrissi
Journal:  BMJ Case Rep       Date:  2017-10-20

3.  Critical gastrointestinal bleed due to secondary aortoenteric fistula.

Authors:  Mohammad U Malik; Enver Ucbilek; Amanpreet S Sherwal
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-12-11

4.  A case report of successful treatment of secondary aortoenteric fistula complicated with gastrointestinal bleeding and retroperitoneal abscess in an elderly patient.

Authors:  Chunyan Jiang; Xueming Chen; Jianshe Li; Hongwei Li
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.